Top in cardiology: Highlights from the American College of Cardiology Scientific Session
Click Here to Manage Email Alerts
The American College of Cardiology recently held its annual meeting. Healio’s coverage of the virtual conference made up the top stories in cardiology last week.
The top story was a secondary analysis of the STRENGTH trial, which showed that daily omega-3 carboxylic acid supplementation had a neutral impact on cardiovascular risk and adverse cardiovascular events.
Another story was about a trend in influenza vaccination among patients with CVD. The study showed that only half of these patients received the vaccine in the last year, and Black and Hispanic patients were less likely than white patients to be vaccinated.
Read these and more stories from the conference below:
New STRENGTH analysis puts spotlight on CV impact of omega-3 fatty acids
Higher blood levels of eicosapentaenoic acid 1 year after daily omega-3 carboxylic acid supplementation were not associated with lower cardiovascular risk, according to a secondary analysis of the STRENGTH trial. Read more.
Half of patients with CVD report they received influenza vaccine in past year
Among patients with CVD living in the U.S., only half reported that they received an influenza vaccine in the past year, according to data presented at the virtual American College of Cardiology Scientific Session. Read more.
Sacubitril/valsartan not superior to valsartan alone in advanced HFrEF: LIFE
In patients with advanced heart failure, sacubitril/valsartan was not superior to valsartan for reducing N-terminal pro-B natriuretic peptide levels at 24 weeks, according to the results of the LIFE trial. Read more.
INSPIRATION-S: Statin therapy fails to prevent thrombosis, death in severe COVID-19
Atorvastatin therapy did not reduce risk for venous or arterial thrombosis or all-cause death among patients with COVID-19 admitted to the ICU compared with placebo, according to data from the INSPIRATION-S study. Read more.
ACTION: Rivaroxaban-based anticoagulation strategy fails to improve outcomes in COVID-19
A rivaroxaban-based anticoagulation strategy did not improve outcomes and increased bleeding in patients hospitalized with COVID-19 compared with standard hospital prophylaxis, according to data from the ACTION trial. Read more.